News

The phase 3 rivipansel evaluating safety, efficacy and time to discharge (RESET) study evaluated 345 patients who were randomised 1:1 to receive rivipansel or placebo, administered intravenously every

The agreement is an amendment to the terms of the 2006 tivozanib license agreement between Kyowa Kirin and AVEO which granted AVEO exclusive rights of tivozanib in all

The product is the generic version of Pierre Fabre Médicament’s Navelbine®, which is indicated for the treatment of advanced non-small-cell lung cancer (NSCLC) and advanced breast cancer. The

Nucala, a pre-filled pen and a pre-filled safety syringe, is claimed to be the only monthly anti-IL5 biologic approved in Europe to treat patients with severe eosinophilic asthma

The agreement gives Exelixis the opportunity to in-license as many as six programs from Aurigene, which has developed a focused approach to drug discovery that targets differentiated first-in-class

The late-stage trial assessed the efficacy and safety of Kisqali plus fulvestrant combination in postmenopausal women having hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or

As previously announced, under the terms of the transaction, Pfizer owns a 32% equity stake in the joint venture and GSK owns 68%. The combined business, which will

The approval was based on data from the phase III ARAMIS trial, which assessed Nubeqa plus androgen deprivation therapy (ADT). According to the company, the trial showed a

As Array becomes part of Pfizer, it brings an impressive existing portfolio that includes the approved combined use of BRAFTOVI (encorafenib) and MEKTOVI (binimetinib) for the treatment of